Positron emission tomography (PET) provides important information in studies centered on the drug plasma concentrations-clinical effectiveness relationship, as it directly allows measuring of drug binding to pharmacologically relevant receptors in the brain. Such studies have been carried out for many antipsychotics, the binding of which to central dopamine D2 receptors can be observed with PET (Grunder et al. 2011) . A study showed a 50-70 % D2-receptor occupancy by therapeutic doses (4-10 mg/day; 5.7±1.4 mg/day [mean ± SD]) of the antipsychotic drug flupentixol, which reportedly lead to flupentixol plasma concentrations between 0 and 6 ng/ml (1.47±0.97 ng/ml) after oral administration of this drug to 13 patients (Reimold et al. 2007) . Flupentixol is available as a 1:1 mixture of the geometric isomers cis-and trans-isomers (Z-and E-isomers, respectively) for oral administration, while the depot preparation flupentixol decanoate contains only cis-flupentixol. Only cis-flupentixol is considered to be pharmacologically active with regard to its affinity for dopamine (and serotonin) receptors, as also shown in clinical studies in which clinical efficacy of cis-flupentixol (α-flupentixol; Z-flupentixol) was found to be superior to that of trans-flupentixol (β-flupentixol; E-flupentixol) (Johnstone et al. 1978 ). An analysis of three-dimensional structures and molecular electrostatic potentials confirms the higher receptor affinities of cis-flupentixol in comparison to the trans-isomer (Sylte and Dahl 1991). In the already mentioned PET study with flupentixol, the presented drug plasma concentrations appear to be those of the sum of cis-and trans-flupentixol, as the standard analytical technique used by MDS Pharma Services (Fehraltorf, Switzerland) was not developed for the separation of these isomers (Reimold et al. 2007; and Petra Struwe, Celerion, Fehraltdorf, personal communication).
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Recently, the AGNP-TDM group (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) ) recommended published updated consensus guidelines for therapeutic drug monitoring in psychiatry: The therapeutic reference range (recommended plasma drug concentration) for the antipsychotic drug flupentixol (flupenthixol) was given as 1-10 ng/ml. This range is related to the sum of the cis-and the trans-isomers concentrations, and the recommended range is mainly based on 2 studies (Reimold et al. 2007; Balant-Gorgia et al. 1985) . The question arises whether after analysis of the literature, which considers pharmacological and pharmacokinetic differences between the cis-and trans-isomers of flupentixol, the recommended plasma concentration range of flupentixol may still be considered as valid.
Only few studies considered the existence of two geometric isomers of flupentixol differing by their properties. In 1985, a lower threshold of 2 ng/ml flupentixol was reported for satisfactory antipsychotic effect (Balant-Gorgia et al. 1985) . The authors did not use a stereoselective method, but divided the measured flupentixol concentration by 2 in order to consider only the concentration of cis-flupentixol, with the assumption, that cis-and trans-flupentixol plasma concentrations are equal in flupentixol treated patients. As a result, patients treated orally with 6-12 mg/day flupentixol achieved maximally 10 ng/ml cis-+ trans-flupentixol concentrations. However, in 1987, the same group (Balant-Gorgia et al. 1987) developed a stereospecific assay which revealed that in a group of patients treated orally with flupentixol, 59 % of the patients had a trans-/cis-flupentixol ratio in plasma between 1.5 and 2.5 (range 0.77-6.0). In 93 % of the cases, the inactive trans-isomer concentration exceeded that of the active cis-isomer. A graphic presentation suggests that in patients treated orally with 4-15 mg/day flupentixol, cisflupentixol concentrations vary between 0.5 and 5 ng/ml. This suggests that in the PET study (Reimold et al. 2007 ), significantly lower concentrations than 0.5-2 ng/ml cisflupentixol lead to 50-70 % D2-receptor occupancy.
Other authors developed stereoeselective methods of flupentixol in the blood of patients treated with flupentixol. Ulrich (1995) described disappearance of cis-flupentixol exposed to daylight and its trans-isomerization to transflupentixol until a 1:1 mixture of both isomers is reached. In the clinical part of his study, none of the few patients treated with 20 mg/day flupentixol p.os had cis-flupixol levels >10 ng/ml. After a treatment of dozens of patients with 2.5-40 mg/day oral flupentixol, cis-flupentixol levels were found to be <10 ng/ml in all but one patient. These authors carefully avoided exposition of the probes to daylight during drug analysis (Walter et al. 1998) . In cocaine dependent patients treated with low doses (2.5 or 5 mg/day) of oral flupentixol, cis-flupentixol plasma trough levels as measured with a stereoselective method only reached 0.53± 0.2 ng/ml (means ± SEM) (Evans et al. 2001) .
Several authors did not mention the existence of cistrans isomerism of flupentixol in their publications, where they proposed non-stereoselective assays for therapeutic drug monitoring (Gutteck and Rentsch 2003; Kumazawa et al. 2000) .
In conclusion, considering the pharmacological and pharmacokinetic differences between cis-and trans-flupentixol, therapeutic monitoring studies with oral flupentixol in psychiatric patients should include stereoselective assays in conditions protected from daylight. Moreover, more data are needed to clearly define an optimal therapeutic range for cis-flupentixol plasma levels, as almost all studies were performed in a limited number of patients treated with relatively low doses (2.5-20 mg/day) of flupentixol.
Tentatively, a therapeutic reference range/recommended cis-flupentixol concentration range of 0.5-5 ng/ml is proposed.
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